The PROSPECT II study was published in the March 13th issue of The Lancet,
finding that IVUS+NIRS imaging can detect plaques at increased risk for future adverse cardiac outcomes.VIEW ARTICLE VIEW ARTICLE

Our Culture

Charting the uncharted territories of vascular disease doesn’t happen overnight. It takes passion, grit, and heart to never stop seeking solutions. The kind of determination that has fueled Infraredx for nearly 30 years.

READ MORE

Our Leadership

Nozomu “Fuji” Fujita

President and CEO, Infraredx, a Nipro Company General Manager, Nipro Vascular Business Division


Having been employed at Nipro for nearly 25 years, Nozomu Fujita takes the Nipro creed of “Willingness” to heart. He joined the company immediately after earning his master’s degree in engineering from the Department of Applied Chemistry at the esteemed Osaka Institute of Technology, and his career grew as Nipro continued to expand.

Steve Sum, PhD

Sr. Vice President of Technology Innovation and Regulatory


Steve Sum is an academic at heart. After earning a BSc in Chemistry & Mathematics at the University of Waterloo in Ontario, Canada, he went straight on to earn a MSc in Information & Systems Science from Carleton University, and then a PhD in Chemometrics and Analytical Chemistry from the University of Delaware.

David Barone

Vice President of Product Development


If not for his love of music, David Barone might never have joined Infraredx. When then-Director of Catheter R&D, Jerry Brightbill, asked him to play drums with his band for the Infraredx holiday party in 2005, David found himself at founder Jim Muller’s home, surrounded by the entire company. Brightbill, who plays guitar had joined Infraredx a few years earlier and, during jam sessions, would often ask David to check them out.

Events

Don’t Guess. See.

Gain twice the insights into Coronary Artery Disease with IVUS+NIRS. See how combination IVUS+NIRS imaging offers cardiologists unparalleled insights into the role LCP plays in heart disease.

Amid COVID-19 concerns, we are unable to exhibit in person and will be participating in virtual conferences. Please check back periodically for event updates or for more information send us an email

June 11-12, 2021
OPCI 2021
July 1-2, 2021
ML CTO 2021
Palais de la Mediterranee, Nice and Presented Virtually Online
July 29-31, 2021
CVI 2021
August 27-30, 2021
ESC 2021
Presented Virtually
November 4-6, 2021
TCT 2021
Orlando, Florida and Broadcasted Live

News

Infraredx, a Nipro Company, and Nipro Medical Corporation (NMC), a leading Renal, Medical, Surgical, and International Radiology products manufacturer, announced a collaboration between the two entities to deliver cutting-edge technologies to the U.S. market.

Infraredx, a Nipro Company, and Nipro Medical Corporation (NMC), a leading Renal, Medical, Surgical, and International Radiology products manufacturer, announced a collaboration between the two entities to deliver cutting-edge technologies to the U.S. market. NMC announced today that it will establish a Vascular Division in the U.S., to help build a world-class vascular product portfolio to address the unmet needs in the vascular space. This strategic move aligns with Nipro Corporation’s long-term goals to enhance patient care and expand their vascular footprint.

Read More
Infraredx, a Nipro Company, and B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc., Announce Strategic U.S. Collaboration to Execute the IDE Clinical Trial for the SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter

Following Receipt of FDA Breakthrough Device Designation, Market Leading Global Organizations Strengthen their Cooperation to Navigate U.S. Regulatory Pathway.  B. Braun Interventional Systems Inc. (BIS) announced today that they will collaborate with Infraredx, a Nipro Company, to accelerate the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial for the B. Braun SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter, which received FDA Breakthrough Device Designation in late 2019. This announcement furthers the long-term global cooperation between the B. Braun Group of Companies and Japan-based Nipro Corporation to advance coronary artery disease management.

Read More
Results of the PROSPECT II Natural History Study Demonstrate High-Risk Plaques Identified by NIRS+IVUS Imaging are Linked to Future Coronary Events

Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced positive results from the PROSPECT II and PROSPECT ABSORB studies, presented today as a late-breaking clinical trial at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. The PROSPECT II study demonstrated the ability of near-infrared spectroscopy (NIRS) imaging plus intravascular ultrasound (IVUS) to identify coronary plaques responsible for future coronary events. The randomized substudy PROSPECT ABSORB, which was simultaneously published in the Journal of the American College of Cardiology (JACC), showed treatment of high-risk vulnerable plaques with a bioresorbable vascular scaffold (BVS) was safe and substantially associated with favorable long-term clinical outcomes compared to guideline-directed medical therapy (GDMT) alone.

Read More
Dr. Giulio Guagliumi discusses the “use of IVUS+NIRS imaging for decision making in acute coronary syndrome.” 

Dr. Giulio Guagliumi from ASST Papa Giovanni XXIII in Bergamo, Italy discusses the “use of IVUS+NIRS imaging for decision making in acute coronary syndrome,” during the 2020 EuroPCR e-course. The course discusses:

  • The frequency of culprit lesion ambiguity in ACS
  • The value of IVUS+NIRS imaging in challenging scenarios
  • Integrating the information provided by IVUS+NIRS imaging in the clinical decision-making process.
Read More

Careers

Thank you for your interest in employment opportunities at Infraredx, a Nipro Company.

We are happy to receive your application. If you are interested in future opportunities, please send your CV to HR@infraredx.com

© 2020 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative